Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

CStone Pharma (2616 HK): 1H25 Revenue Drop Seems Temporary Hiccup; Sugemalimab Trigger Awaited

CStone Pharma (2616 HK): 2025 Seen Off Well, 2026 Would Be Crucial. A Possible Turnaround On Cards?

CStone Pharma (2616 HK): Placement to Fund R&D; Sugemalimab Changes Fortune For Now, What Lies Next?

Equity Bottom-Up

CStone Pharmaceuticals / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cstone-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:27882:1" rel="noopener">CStone Pharmaceuticals (2616 HK)</a> posted revenue of RMB 205.1M (vs RMB 49.4M in 1H25) as sales of Gavreto (pralsetinib) increased substantially following its successful inclusion in the NRDL.</li>
<li>R&amp;D expenses increased 95% to RMB 205.5M due to increased ongoing clinical trials. Company ended 1H26 with a loss of RMB 252.3M vs loss of RMB 270.2M in 1H25.</li>
<li>Sugemalimab awaiting launches in new overseas territories, Aykavit and Gavreto sales slowly picking and CS2009 showing encouraging trial results pose a positive outlook about the company.</li>
</ul>



CStone Pharmaceuticals (2616 HK) posted revenue of RMB 205.1M (vs RMB 49.4M in 1H25) as sales of Gavreto (pralsetinib) increased substantially following its successful inclusion in the NRDL.
R&amp;D expenses increased 95% to RMB 205.5M due to increased ongoing clinical trials. Company ended 1H26 with a loss of RMB 252.3M vs loss of RMB 270.2M in 1H25.
Sugemalimab awaiting launches in new overseas territories, Aykavit and Gavreto sales slowly picking and CS2009 showing encouraging trial results pose a positive outlook about the company.


CStone Pharma (2616 HK): Pharma Products Picking Up, Pipeline 2.0 Showing Potential